Combination of Imvotamab and Loncastuximab Tesirine Shows Enhanced Anti‐Tumor Activity in a Preclinical Model of Non‐Hodgkin’s Lymphoma
Kathryn Logronio(IGM Biosciences (United States)), M. F. Kotturi(IGM Biosciences (United States)), Poonam Yakkundi(IGM Biosciences (United States)), Bruce A. Keyt, M. K. Leabman(IGM Biosciences (United States)), Genevive Hernandez(Sutro Biopharma (United States)), Angus M. Sinclair(LabGenius (United Kingdom)), Mugdha V. Joglekar(Camden and Campbelltown Hospitals), Thomas Manley(IGM Biosciences (United States)), Miho Oyasu(IGM Biosciences (United States)), Albert F. Candia(Dynavax Technologies (United States)), Stephen F. Carroll(IGM Biosciences (United States))
Cited by 2
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
|Proceedings of the National Academy of Sciences|1986|518